Prosecution Insights
Last updated: April 19, 2026

Celgene Corporation

9 pending office actions

Portfolio Summary

9
Total Pending OAs
6
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18419894 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF RAHMANI, NILOOFAR 1691 Non-Final OA Jan 23, 2024
18573723 CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH VALLE, ERNESTO 1623 Non-Final OA Dec 22, 2023
18557852 PKC-Theta Modulators RAO, PADMAJA S 1627 Final Rejection Oct 27, 2023
18223768 Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 VALLE, ERNESTO 1623 Non-Final OA Jul 19, 2023
17995915 METHODS FOR TREATING ANEMIA USING AN ACTRIIB LIGAND TRAP AND FEDRATINIB BORGEEST, CHRISTINA M 1675 Final Rejection Oct 10, 2022
17817777 Composition and Methods for Selective Degradation of Engineered Proteins BOWLES, DAVID PAUL 1654 Final Rejection Aug 05, 2022
17867294 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME NESTOR, DONNA MICHELLE 1627 Final Rejection Jul 18, 2022
17776561 PEDIATRIC FORMULATIONS FOR TREATMENT OF CANCER COHEN, MICHAEL P 1612 Final Rejection May 12, 2022
17075594 METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE BUTTICE, AUDREY L 1647 Final Rejection Oct 20, 2020

Managing Celgene Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month